Senti Biosciences Holdings Inc (SNTI) FinancialsSNTISenti Biosciences Holdings Inc

Evaluating the bottom line, Senti Biosciences Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -85229.41%, while the net margin is -75000.00%. These profitability ratios, combined with a Return on Equity (ROE) of -466.46%, provide a clear picture of how effectively SNTI converts its operational activities into shareholder value.

In the context of the broader market, SNTI competes directly with industry leaders such as AQB and FBLG. With a market capitalization of $5.87M, it holds a significant position in the sector. When comparing efficiency, SNTI's gross margin of 100.00% stands against AQB's N/A and FBLG's N/A. Such benchmarking helps identify whether Senti Biosciences Holdings Inc is trading at a premium or discount relative to its financial performance.

Senti Biosciences has reported zero revenue for multiple quarters, with a projected revenue of only $22,000 in Q4 2025. The company has consistently posted negative net income, with losses reaching -$18.13 million in Q3 2025. The gross margin is currently at 100% for the next quarters, but this is due to negligible revenue, not operational success.